Genitourinary Cancer News

Immune checkpoint inhibitor therapy appeared associated with an increased risk for major adverse cardiovascular events among patients with cancer and a prior history of cardiovascular disease, according to results of a retrospective study.

Before the opening of City of Hope’s new comprehensive cancer center, many residents of Orange County, California, faced a long commute for advanced cancer care.

Certain patient demographics, including race and ethnicity and underlying primary malignant neoplasm, appeared associated with delays in cancer treatment among patients with COVID-19.

Targeted cancer therapy had a higher association with risk for major adverse cardiovascular events than cytokine therapy among patients with advanced renal cell carcinoma, according to study results.

Although the number of Americans insured through Medicaid has increased during the past decade, barriers to cancer care access exist among Medicaid beneficiaries across high-quality centers, according to study results in JAMA Network Open.

Researchers at New York University, Weill Cornell Medicine and New York Genome Center have developed and tested a two-step approach that uses whole-exome sequencing to find genes and pathways that predict response to immunotherapy.

Patients who received treatment for high-grade nonmuscle-invasive bladder cancer had similar outcomes irrespective of European Association of Urology risk status, results of a retrospective study showed.

The Parker Institute for Cancer Immunotherapy presented $4.5 million in fellowship and scholarship awards to nine graduate and postdoctoral researchers.

The FDA granted fast track designation to several oncology and hematology therapies.

Men appeared to have a higher risk for cancer than women at most shared anatomic sites, according to study results published in Cancer.